A sponsor that seeks to piggyback on a potential competitor's study results may want to first ensure that FDA agrees the data prove the point the company is trying to make.
Such was the case at the Aug. 4 advisory committee review of Egalet Corp.'s long-acting opioid Arymo ER (morphine...